ADX-631 / Aldeyra - LARVOL DELTA

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable (Businesswire) - "Aldeyra Therapeutics, Inc...today announced advancement of new RASP modulators and recent preclinical data in obesity in conjunction with an Investor Roundtable scheduled to begin at 8:00 a.m. ET today...Based on new results in a preclinical model of obesity, novel RASP modulator ADX-743 was advanced to Investigational New Drug (IND)-enabling studies...Pending additional results, Aldeyra expects to submit an IND application for ADX-743 or an alternative RASP modulator for obesity or hypertriglyceridemia in 2025...Phase 1 clinical testing of ADX-248 is expected to begin in the second half of 2024... Aldeyra expects to submit an IND application for ADX-631 or an alternative RASP modulator for the treatment of dry AMD or geographic atrophy in the first half of 2025."

IND • New P1 trial • Atopic Dermatitis • Dermatology • Dry Age-related Macular Degeneration • Hypertriglyceridemia • Metabolic Disorders • Obesity • Ophthalmology